Rtw Investments Adds $13M in Immatics N.V. ($IMTX)
Rtw Investments has increased its stake in IMTX by 12.6% as of its latest 13F filing.
Key Points
- Rtw Investments added 1.44 million shares to its IMTX holdings, a 12.6% increase, bringing its total to 12.87 million shares valued at $120.7 million.
- Shares of IMTX traded at $9.38, with analysts from Chardan Capital maintaining a 'buy' rating and a $25 price target as of May 19, 2026.
- T. Rowe Price Investment Management, Inc. grew its IMTX holdings by 193,006 shares to 21.65 million, valued at $213.1 million.
Rtw Investments has increased its stake in IMTX, adding 1,435,986 shares according to its latest 13F filing with the SEC, reflecting holdings as of the most recent reporting period. This brings Rtw's total holdings to 12,869,340 shares, marking a 12.6% increase. The value of this position is approximately $120.7 million.
What Changed in Rtw Investments' IMTX Position
Rtw Investments boosted its holdings in IMTX by 1,435,986 shares, a 12.6% increase from its previous count of 11,433,354 shares. This move raises its total to 12,869,340 shares, valuing the stake at about $120.7 million.
Other Institutional Activity in IMTX
Other institutional investors have also been active in IMTX. T. Rowe Price Investment Management, Inc. increased its position by 193,006 shares, bringing its total to 21,652,162 shares, worth approximately $213.1 million. Baker Bros. Advisors LP, however, reduced its holdings by 1,177,401 shares, ending with 10,916,693 shares valued at $107.4 million. Meanwhile, Suvretta Capital Management, LLC maintained its position with 11,190,129 shares, valued at $110.1 million.
IMTX Stock Snapshot
Shares of IMTX were trading around $9.38. However, detailed stock metrics like market cap, P/E ratio, and moving averages were not provided. The stock's performance and valuation are closely watched by investors, especially with recent institutional interest.
Analysts Set New Price Targets
On May 19, 2026, Chardan Capital maintained its 'buy' rating on IMTX with a price target of $25. Jefferies assumed a 'buy' rating with an $18 target on March 16, 2026. The consensus among analysts remains positive, with multiple firms maintaining 'buy' ratings and setting targets between $10 and $25.
About IMTX
IMTX operates in the biotechnology sector, focusing on developing innovative therapies. The company is involved in research and development aimed at treating various diseases. It is known for its cutting-edge approaches and collaborations within the industry.
Bottom Line
Rtw Investments' recent increase in IMTX holdings underscores ongoing interest in the company from institutional investors. The 13F filing provides a backward-looking view of Rtw's position as of the reporting period, offering insights into its investment strategy. Analysts' continued 'buy' ratings suggest optimism about IMTX's potential.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.